Miikka Vikkula/LinkedIn
Dec 25, 2025, 13:41
Miikka Vikkula on a Treatment Advance: How Sirolimus Dosing Can Be Adapted for Vascular Malformations
Miikka Vikkula, Vice President at International Society for the Study of Vascular Anomalies (ISSVA), shared a post on LinkedIn:
“Congratulations Emmanuel on this online publication showing how sirolimus treatment can be adapted to patients’ needs. Most patients with slow-flow vascular malformations benefit to some extent, and many experience significant symptom reduction even with intermittent dosing. This is a big step forward in the multimodal management of vascular malformations”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026
-
Jul 19, 2026, 16:52Shamee Shastry: Sometimes the Answer is Not in the Test Tube Alone, but at the Patient’s Bedside
-
Jul 19, 2026, 16:52Manuela Albisetti: Congratulations to Alessandra Bosch on an Outstanding ISTH 2026 Talk
-
Jul 19, 2026, 16:44Fernanda Orsi: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:37William Aird: A Visual Guide to Understanding von Willebrand Disease